Candesartan

Candesartan cilexetil

Therapeutic Indications

Candesartan is indicated for:

Essential hypertension

Irrespective of gender only Children (1 year - 12 years old) , Adolescents (12 years - 18 years old)

Candesartan is indicated for the treatment of essential hypertension in adults.

For this indication, the medical literature mentions below treatments (click for details):

Treatment 1: Oral - 4-32mg once daily

Heart failure and impaired left ventricular systolic function

Irrespective of gender only Adults (18 years old or older)

Amias is indicated for the treatment of adult patients with heart failure and impaired left ventricular systolic function (left ventricular ejection fraction ≤40%) as add-on therapy to Angiotensin Converting Enzyme (ACE) inhibitors or when ACE inhibitors are not tolerated.

For this indication, the medical literature mentions below treatments (click for details):

Treatment 1: Oral - 4-32mg once daily

Essential hypertension

Irrespective of gender only Adults (18 years old or older)

Candesartan is indicated for the treatment of essential hypertension in adults.

For this indication, the medical literature mentions below treatments (click for details):

Treatment 1: Oral - 8-32mg once daily

Contraindications

Active ingredient Candesartan is contraindicated in the following cases:

Severe hepatic impairment

No gender/age discrimination

Pregnancy

No gender/age discrimination

The use of AIIRAs is not recommended during the first trimester of pregnancy. The use of AIIRAs is contraindicated during the second and third trimesters of pregnancy.

Epidemiological evidence regarding the risk of teratogenicity following exposure to ACE inhibitors during the first trimester of pregnancy has not been conclusive; however a small increase in risk cannot be excluded. Whilst there is no controlled epidemiological data on the risk with AIIRAs, similar risks may exist for this class of drugs. Unless continued AIIRA therapy is considered essential, patients planning pregnancy should be changed to alternative antihypertensive treatments which have an established safety profile for use in pregnancy. When pregnancy is diagnosed, treatment with AIIRAs should be stopped immediately and, if appropriate, alternative therapy should be started.

Exposure to AIIRA therapy during the second and third trimesters is known to induce human fetotoxicity (decreased renal function, oligohydramnios, skull ossification retardation) and neonatal toxicity (renal failure, hypotension, hyperkalaemia).

Should exposure to AIIRAs have occurred from the second trimester of pregnancy, ultrasound check of renal function and skull is recommended.

Infants whose mothers have taken AIIRAs should be closely observed for hypotension.

Aliskiren in patients with diabetes mellitus or renal impairment (GFR <60ml/min/1.73 m²)

No gender/age discrimination

The concomitant use of candesartan with aliskiren-containing products is contraindicated in patients with diabetes mellitus or renal impairment (GFR <60ml/min/1.73m²).

Cholestasis

No gender/age discrimination